Sensei Biotherapeutics’ (FTH) “Buy” Rating Reaffirmed at BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $55.00 price target on the stock. BTIG Research‘s target price would indicate a potential upside of 226.80% from the stock’s current price.

A number of other equities research analysts have also issued reports on FTH. Guggenheim started coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They issued a “buy” rating and a $70.00 target price on the stock. Needham & Company LLC started coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 target price on the stock. TD Cowen initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a “buy” rating on the stock. JonesTrading initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Down 1.5%

FTH stock opened at $16.83 on Tuesday. Sensei Biotherapeutics has a 1 year low of $7.45 and a 1 year high of $42.14. The company has a 50 day moving average of $29.91. The stock has a market cap of $434.89 million, a price-to-earnings ratio of -0.12 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. On average, analysts anticipate that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Institutional Trading of Sensei Biotherapeutics

Large investors have recently modified their holdings of the business. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics during the first quarter valued at about $22,758,000. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Bank of America Corp DE grew its stake in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.